

A randomised trial of paclitaxel combined with platinum-based chemotherapy vs conventional platinum-based chemotherapy in the treatment of women with ovarian cancer

Submission date 06/04/2000	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 06/04/2000	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 29/10/2021	Condition category Cancer	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Ms Claire Amos

Contact details

MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number
NCT00002894

Secondary identifying numbers

Study information

Scientific Title

A randomised trial of paclitaxel combined with platinum-based chemotherapy vs conventional platinum-based chemotherapy in the treatment of women with ovarian cancer

Study objectives

To compare paclitaxel combined with platinum to a control arm of conventional platinum-based chemotherapy in the treatment of women with recurrent ovarian cancer.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Not Specified

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Ovarian cancer

Interventions

Paclitaxel combined with platinum and the other group receives platinum-based chemotherapy (with no paclitaxel)

Intervention Type

Other

Phase

Not Specified

Primary outcome measure

1. Survival time
2. Quality of life
3. Health economics

Secondary outcome measures

Not provided at time of registration

Overall study start date

01/03/1996

Completion date

31/03/2002

Eligibility

Key inclusion criteria

1. Recurrent epithelial ovarian cancer previously treated with chemotherapy
2. Treatment-free interval of at least 6 months

Participant type(s)

Patient

Age group

Not Specified

Sex

Female

Target number of participants

800 in 5 countries

Total final enrolment

802

Key exclusion criteria

Does not meet inclusion criteria

Date of first enrolment

01/03/1996

Date of final enrolment

31/03/2002

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

MRC Clinical Trials Unit

London

United Kingdom

NW1 2DA

Sponsor information

Organisation

Medical Research Council (MRC) (UK)

Sponsor details

20 Park Crescent

London

United Kingdom

W1B 1AL

+44 (0)20 7636 5422

clinical.trial@headoffice.mrc.ac.uk

Sponsor type

Research council

Website

<http://www.mrc.ac.uk>

Funder(s)

Funder type

Research council

Funder Name

Medical Research Council (MRC) (UK)

Alternative Name(s)

Medical Research Council (United Kingdom), UK Medical Research Council, MRC

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

Not provided at time of registration

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	21/06/2003		Yes	No
Plain English results		08/09/2009	29/10/2021	No	Yes